Marco Polo Well drilling, page-14

First 14 Last

Share
Profile

Follow
brushup

2,727 Posts.

170

26/08/16

15:49

Post #: 18716682
Share

Originally posted by Autosime ↑

Wazz
simply a follow up email to the post about the discussion with the MDA

Aussierat
there is a thing in investment analysis called the funding Gap. it essentially looks at what is the gap or excess funding needs are to increase revenue. the bigger the gap, the riskier the investment. By definition if a business always needs 1.20 in funding to earn a dollar in net revenue then you have a very poor business. Even if we get IP of 100 from all three wells, that wont be anywhere near enough to fund another well let alone the three planned. the 500k remaining will fund corp costs for 6 months and thus why another raising is a shoe in. Now despite what you and many on here may argue , that raising are a part of business on the ASX, that is simple no true, good business earn more than they need to fund growth and some borrow based on existing revenue stream. Continual CRs are signs of poor businesses. Everytime AKK taps the market say for 1.8m the dilute every asset they hold by 25-30%. What is worse that dilution doesn't go into just drilling, it goes into keeping the lights on and paying the salaries for the boys

can someone tell me why these guys gave themselves a pay increase - what exactly have they achieved

Expand

good question Autosime have been decimated SP at ACR and management get massive bonus RCG achieve massive profit and SP dives 15% Main reason I got out a big loss (AKK) like ACR I think AKK management look after management before shareholders.

AKK Price at posting: 0.7¢ Sentiment: Hold Disclosure: Not Held
8 Upvote

0 Great analysis

Reply

Top Stories

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger